In HR-proficient cancers, induction of synthetic lethality can be achieved through HRR inhibition by using specific inhibitors of ATM, ATR, Topoisomerase 2 or Bromodomain Containing 4 (BRD4) to create a BRCAness phenotype. Here, BRD4 is linked to cancer.